MedTrace Logo

Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

NCT06531863 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-02-14

No results posted yet for this study

Summary

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are:

Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo.

Participants will consume an 8-week supplement of both:

* 1,330mg/day curcumin
* 350mg/day epigallocatechin gallate (EGCG)

Conditions

  • Mood Disturbance

Interventions

DIETARY_SUPPLEMENT

Curcumin

1,330 mg curcumin

DIETARY_SUPPLEMENT

Epigallocatechin Gallate

350 mg Epigallocatechin gallate (EGCG)

OTHER

Placebo

Placebo to be consumed after randomization.

Sponsors & Collaborators

  • Auburn University

    lead OTHER

Principal Investigators

  • Andrew D Fruge, PhD · Auburn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2025-05-01
Completion
2025-08-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06531863 on ClinicalTrials.gov